In a phase I/II randomized trial, the addition of dalotuzumab (a selective anti-IGF1R antibody) to erlotinib did not improve efficacy outcome in patients with refractory advanced NSCLC [35]. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.